DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc
(Nasdaq: ALKS) today announced the appointment of a new independent
director, Nancy S. Lurker, to the company's Board of Directors (the
Board). Ms. Lurker is a seasoned healthcare executive and
experienced board member who brings decades of pharmaceutical and
biotechnology industry leadership experience and strong commercial
expertise, including a track record of successful U.S. and global
pharmaceutical product launches.
"Nancy brings to the Board deep biopharmaceutical industry
experience spanning executive leadership, governance, strategic
planning, product development and commercialization. This broad
expertise will be an important asset to the Board and the company
as we drive continued growth of our existing portfolio of
proprietary products, expand our portfolio and bring new products
to market," said Richard Pops, Chief Executive Officer of Alkermes.
"Nancy's appointment reflects the Board's ongoing commitment to
robust board refreshment and diversity and to the importance of
aligning the qualifications and experience of our directors with
our strategy and growth opportunities. We welcome Nancy to the
Board and look forward to working together."
"I am delighted to join Alkermes' Board and to work with the
management team as the company continues to advance its important
work to bring innovative medicines to patients living with serious
neurological and psychiatric conditions," said Ms. Lurker. "I look
forward to sharing my insights and supporting the company as it
continues to advance its strategy and builds upon its position as a
leader in the field of neuroscience."
About Nancy Lurker
Ms. Lurker most recently served as
Chief Executive Officer of EyePoint Pharmaceuticals, Inc., a
publicly-traded specialty biopharmaceutical company, from 2016 to
July 2023, at which time she
transitioned to her current role as Executive Vice Chair of
EyePoint Pharmaceuticals' board of directors. She also served as
President of EyePoint Pharmaceuticals from 2016 to January 2023. Prior to EyePoint Pharmaceuticals,
Ms. Lurker served as President and Chief Executive Officer and a
director of PDI, Inc. (now Interpace Diagnostics Group, Inc.), a
publicly-traded healthcare commercialization company, and as Senior
Vice President and Chief Marketing Officer of Novartis
Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG.
Prior to that, Ms. Lurker held various senior positions at other
leading pharmaceutical companies including Pharmacia
Corporation (now a part of Pfizer, Inc.), ImpactRx and
Bristol-Myers Squibb Company.
Ms. Lurker currently serves on the board of directors of
EyePoint Pharmaceuticals, Altasciences, LLC, a private contract
research organization and National Sanitation Foundation, a
not-for-profit organization dedicated to improving human health
through quality standards. She previously served on the boards of
directors of the Cancer Treatment Centers of America, and current
and formerly publicly-traded companies Aquestive Therapeutics,
Inc., X4 Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc.,
Mallinckrodt plc, PDI, Inc., Elan
Corporation, plc, and ConjuChem Biotechnologies. Ms. Lurker holds a
B.S. in Biology from Seattle Pacific
University and an M.B.A. from the University of Evansville.
About Alkermes plc
Alkermes plc is a global
biopharmaceutical company that seeks to develop innovative
medicines in the field of neuroscience. The company has a portfolio
of proprietary commercial products for the treatment of alcohol
dependence, opioid dependence, schizophrenia and bipolar I
disorder, and a pipeline of clinical and preclinical candidates in
development for neurological disorders. Headquartered in
Dublin, Ireland, Alkermes has a
research and development center in Waltham, Massachusetts; a research and
manufacturing facility in Athlone, Ireland; and a manufacturing facility in
Wilmington, Ohio. For more
information, please visit Alkermes' website at
www.alkermes.com.
Note Regarding Forward-Looking Statements
Certain
statements set forth in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to, statements concerning: the company's
expectations concerning its future financial and operating
performance, business plans or prospects, including its
ability to drive continued growth of its proprietary products,
expand its portfolio and bring new products to market; and the
potential therapeutic, clinical and commercial value of the
company's investigational and commercial products. The company
cautions that forward-looking statements are inherently uncertain.
The forward-looking statements are neither promises nor guarantees
and they are necessarily subject to a high degree of uncertainty
and risk. Actual performance and results may differ materially from
those expressed or implied in the forward-looking statements due to
various risks and uncertainties, including those risks and
uncertainties described under the heading "Risk Factors" in the
company's Annual Report on Form 10-K for the year ended
Dec. 31, 2023 and in subsequent
filings made by the company with the U.S. Securities and Exchange
Commission (SEC), which are available on the SEC's website at
www.sec.gov. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Except as required by law, the
company disclaims any intention or responsibility for updating or
revising any forward-looking statements contained in this press
release.
Alkermes
Contacts:
|
|
|
For
Investors:
|
Sandy Coombs
|
+1 781 609
6377
|
For Media:
|
Katie
Joyce
|
+1 781 249
8927
|
Photo -
https://mma.prnewswire.com/media/2356703/Alkermes_Lurker_Headshot_ID_5b29d1c906a4.jpg
Logo -
https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/alkermes-announces-appointment-of-nancy-s-lurker-to-board-of-directors-302082266.html